The risk of acquiring herpes simplex virus type 2 (HSV-2) was reduced by half among women in the VOICE trial who used a vaginal gel containing the antiretroviral (ARV) drug tenofovir regularly. This is according to researchers from the U.S. National Institutes of Health-funded Microbicide Trials Network (MTN) who conducted the study. The findings provide additional evidence that tenofovir gel, a product developed to protect against HIV, could potentially help in ...
Read More
You have just read an article categorized health
titled Tenofovir Gel Use With Lower HSV-2 Risk in Women.
Written by:
editor -
Tuesday, October 28, 2014
There are currently no comments for "Tenofovir Gel Use With Lower HSV-2 Risk in Women"
Post a Comment